Fig 1: ADORA2A-AS1 repressed AKT pathway. (A) AKT phosphorylation levels in SNU-398 cells with ADORA2A-AS1 overexpression or control were measured by Western blot. (B) AKT phosphorylation levels in SNU-398 cells with ADORA2A-AS1 silencing or control were measured by Western blot. (C) MMP2 and BIRC7 transcript levels in SNU-398 cells with ADORA2A-AS1 overexpression or control were measured by qRT-PCR. (D) MMP2 and BIRC7 protein levels in SNU-398 cells with ADORA2A-AS1 overexpression or control were measured by Western blot. (E) MMP2 and BIRC7 transcript levels in SNU-398 cells with ADORA2A-AS1 silencing or control were measured by qRT-PCR. (F) MMP2 and BIRC7 protein levels in SNU-398 cells with ADORA2A-AS1 silencing or control were measured by Western blot. (G) The correlation between MMP2 and ADORA2A-AS1 expression in hepatocellular carcinoma (HCC) tissues analyzed using the RNA-seq data from The Cancer Genome Atlas (TCGA) project. n = 360, p < 0.0001, r = -0.3166 by Pearson correlation analysis. (H) The correlation between MMP2 and ADORA2A-AS1 expression in our HCC cohort. n = 76, p < 0.0001, r = -0.4625 by Pearson correlation analysis. (I) The correlation between BIRC7 and ADORA2A-AS1 expression in HCC tissues analyzed using the RNA-seq data from TCGA project. n = 360, p < 0.0001, r = -0.2428 by Pearson correlation analysis. (J) The correlation between BIRC7 and ADORA2A-AS1 expression in our HCC cohort. n = 76, p = 0.0004, r = -0.3941 by Pearson correlation analysis. For (C, E), results are presented as mean ± SD based on three independent experiments. **p < 0.01, ***p < 0.001 by Student’s t-test (C) or one-way ANOVA followed by Dunnett’s multiple comparisons test (E).